Novo Nordisk Pulls the Plug on Two More Heart Drug Trials The recent decision by Novo Nordisk A/S to halt two more trials of its experimental cardiovascular drug ziltivekimab is a stark reminder that even the most ambitious pharmaceutical companies can falter.
The company had pinned much hope on diversifying into the cardiovascular space, but the writing was on the wall after the July disclosure that ziltivekimab failed to reduce major adverse cardiovascular events in a late stage trial.
An independent data monitoring committee has now found a "low likelihood" that the two additional heart failure studies would yield different results.